News | July 17, 2014

CVS Caremark Research Finds Eliminating Medication Copays Post Heart Attack Can Improve Health Outcomes for Non-white Patients

Analysis demonstrates how the Value Based Insurance Design (VBID) approach significantly increases adherence and reduces disparities in cardiovascular care

CVS Caremark Study Copay Heart Attack Non-white Patient Outcomes

July 17, 2014 — A clinical study by researchers at CVS Caremark, Aetna and Brigham and Women’s Hospital published in the May issue of Health Affairs, finds that eliminating copays for preventive medications prescribed for post-heart attack patients, can significantly improve medication adherence and health outcomes for non-white patients. The analysis suggests that this approach may be an effective strategy for reducing commonly recognized disparities in cardiovascular care related to patient ethnicity and race.

Racial and ethnic disparities in cardiovascular care have been widely documented in the peer-reviewed literature and persist despite overall improvements in cardiovascular mortality and risk factor control. In fact, research by CVS Caremark and Brigham and Women’s Hospital published last year in The American Heart Journal, found that non-white patients had 50 percent greater odds of medication non-adherence to statin medications compared to white patients.

“A series of studies have demonstrated that a Value Based Insurance Design (VBID) approach that reduces or eliminates medication copays is a cost-effective strategy for increasing adherence and improving cardiovascular outcomes,” said Niteesh K. Choudhry, M.D., Ph.D., associate physician, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, associate professor, Harvard Medical School and the lead author of the study. “This new analysis demonstrates that VBID can also reduce disparities in cardiovascular care and health outcomes related to a patient’s race and ethnicity.”

The Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial conducted by Brigham and Women’s Hospital, Harvard Medical School and Aetna (full results of which were previously published in the New England Journal of Medicine in 2011) originally compared full (i.e., no copayments, coinsurance or deductibles) with usual drug insurance coverage for all statin, beta-blockers, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) prescribed after a heart attack. In this new, secondary analysis, the researchers reviewed the data to see whether providing full coverage for post-MI medications had differential effects based on race and ethnicity. More than 2,300 individuals were included in the analysis of which 22.2 percent self-identified as being of non-white race/ethnicity.

The study found that:

  • For all patients, full coverage significantly improved medication adherence.
  • Providing full drug coverage significantly reduced rates of a post-MI major vascular event or revascularization among patients who self-identified as being non-white, but had no impact on clinical events for individuals of white race or ethnicity.
  • Providing full drug coverage reduced total health care spending by 70 percent among patients who self-identified as being non-white.

“There have been a lot of studies demonstrating that disparities in care exist. This study shows us a straightforward way to reduce those disparities and improve health outcomes. We think this is an important contribution,” said William H. Shrank, M.D., MSHS, senior vice president and Chief Scientific Officer of CVS Caremark, and a study co-author. “We should note that the value based insurance design approach of eliminating copayments for maintenance medications after a heart attack is actually a relatively simple, low-risk change that should be considered for broader usage.”

CVS Caremark’s VBID program offering is aimed at removing the barrier of cost to help improve the medication adherence of members. There are currently more than 100 clients enrolled in the program that targets seven chronic conditions. The program is able to provide an increase of 4-9 percent in adherence (as measured by medication possession ratio) and more than 10 percent improvement in moving members with sub-optimal adherence to optimal adherence in certain cardiovascular diseases.

This analysis of medication adherence and the impact on racial and ethnic disparities was supported by an unrestricted research grant from Aetna to Brigham and Women’s Hospital. CVS Caremark has been supporting a multi-year research collaboration with Brigham and Women's Hospital to better understand patient behavior, particularly around medication adherence. Annual excess health care costs due to medication non-adherence in the United States have been estimated to be as much as $290 billion.

For more information: info.cvscaremark.com

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init